Innovent company information, Employees & Contact Information

China's Innovent says its GLP-1 works better than Novo's semaglutide in diabetes study Reuters

Innovent, Lilly's mazdutide trumps Novo's semaglutide in head-to-head diabetes, weight loss study Fierce Pharma

Takeda pays Innovent $1.2B upfront, offers whopping $10B-plus in biobucks for cancer assets Fierce Biotech

Takeda Inks Deal With China’s Innovent to Develop Cancer Drugs Bloomberg

China's Innovent signs cancer therapy deal with Japan's Takeda Reuters

Innovent Announces 2025 Interim Results and Business Updates PR Newswire

Innovent Biologics Challenges Novo and Lilly in China’s GLP-1 Market The Business of Fashion

Innovent raises HKD$4.3B to advance R&D pipeline, global expansion BioWorld MedTech

/C O R R E C T I O N -- Innovent Biologics/ Yahoo Finance

Innovent Biologics has announced $1 Billion ADC Oncology Licensing Agreement with Roche Oncodaily

Chinese drug start-ups poised for 2025 profits, in industry milestone South China Morning Post

Fierce Pharma Asia—Approvals for Innovent, Dizal; BMS partner's bispecific ADC readout Fierce Pharma

Innovent pushes its pancreatic hope | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Roche returns to Innovent Biologics with new $1B biobucks ADC drug deal Fierce Biotech

Innovent's weight-loss drug highlights China challenge for Novo, Lilly Reuters

With China approval, Lilly and Innovent's mazdutide breaks into new class for GLP-1 obesity drugs Fierce Pharma

Innovent Announces Phase 2 Results of Tigulixostat (IBI128, XOI) in Gout Patients were Published at the 27th Asia-Pacific League of Associations for Rheumatology Congress PR Newswire

Innovent revives its US checkpoint plan | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China's NMPA for Chronic Weight Management PR Newswire

Innovent Presents at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire

Innovent takes the dual payload glory | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Innovent Receives U.S. FDA Approval for IND Application of Oral GLP-1R Agonist IBI3032 Yahoo Finance

Fangzhou and Innovent Biologics Form Strategic Alliance for AI-Powered Weight Management Solutions GlobeNewswire

Innovent, awaiting Chinese regulators' verdict, posts another psoriasis win for IL-23 drug Fierce Biotech

Takeda Bets up to $11.4B for Three Innovent ADCs BioSpace

ESMO: Innovent links cytokine fusion protein to responses in colorectal cancer Fierce Biotech

Innovent’s mazdutide superior to Trulicity in Phase III T2D trial Clinical Trials Arena

Innovent Wins China Nod For Obesity Drug Rivaling Novo, Lilly Bloomberg

Innovent wins China approval for obesity drug mazdutide The Pharma Letter

Innovent and SanegeneBio Enter Strategic Collaboration to Develop siRNA Drug for the Treatment of Hypertension PR Newswire

Neutral On Innovent Biologics: Hard To Justify Its Premium (OTCMKTS:IVBXF) Seeking Alpha

Innovent braves bruising cytokine space, linking fusion protein to tumor responses in small study Fierce Biotech

Innovent bags another phase 3 win in China for next-gen Lilly GLP-1 drug Fierce Biotech

Innovent's Tepezza rival one step closer to Chinese approval after phase 3 eye disease win Fierce Biotech

Looking east, Sanofi pens 'pioneering' cancer drug partnership with China's Innovent Fierce Biotech

First-in-Class Dual-Action Cancer Drug: Innovent's IBI363 Heads to Global Phase 3 Trial for Resistant Lung Cancer Stock Titan

[Fact Check] China's Innovent to Relocate Closed US Lab to California 一财全球Yicai Global

Lilly's next-gen obesity drug brings Innovent a phase 3 win in diabetes Fierce Biotech

China's Innovent Biologics secures over $300 million investment from Sanofi Reuters

Innovent Biologics Closes ADC-Focused Maryland Site, Lays Off Researchers BioSpace

Next-gen Lilly obesity drug secures phase 3 win as Innovent readies Chinese approval push Fierce Biotech

Innovent plucks Chinese rights to LG Chem's gout disease treatment in nearly $100M deal Fierce Biotech

Innovent's anti-VEGF drug matches Eylea in phase 2 eye disease trial Fierce Biotech

Eli Lilly dumps Innovent's PD-1 after FDA rebuff, nixing high-profile Chinese cancer drug Fierce Pharma

Next-gen Lilly obesity drug slashes weight in Innovent study—but is it enough to rival Mounjaro? Fierce Biotech

Innovent’s Obesity Drug Shows Similar Weight Loss as Eli Lilly’s Bloomberg

Innovent to take IL-23 psoriasis drug to Chinese regulators after phase 3 win Fierce Biotech

Eli Lilly, Innovent hit with FDA rejection for China-developed lung cancer drug after tough review Fierce Pharma

50.6% Revenue Growth: Innovent's Portfolio Hits 16 Drugs as Biopharma Giant Sets RMB 20B Revenue Target by 2027 Stock Titan

Innovent Bio hopes for plus-sized profits from obesity drug thebambooworks.com

Roche pens $2B biobucks pact with Innovent Biologics for bispecific and cell therapies Fierce Biotech

Eli Lilly Strikes $1 Billion Deal with Innovent for Checkpoint Inhibitor BioSpace

Innovent buys Chinese rights to Incyte drugs for $40M upfront Fierce Biotech

China's Innovent eyeing IPO this year—and could list in U.S. Fierce Biotech

Innovent Bio Completes $300 Million Secondary Offering in Hong Kong NAI500

China's Innovent in $120M bispecifics partnership with EpimAb Fierce Pharma